Not by any rational standard, but the folks who run the Iditarod, Alaska’s famous sled-dog race, seem to think so.  Yikes.

A report published yesterday in the online journal BMC Neurology says that marijuana might help multiple sclerosis patients find relief from the spasticity and muscle spasms caused by the debilitating autoimmune disease.

“We found evidence that cannabis plant extracts may provide therapeutic benefit for MS spasticity symptoms,” said lead researcher Dr. Shaheen Lakhan, executive director of the Global Neuroscience Initiative Foundation. “The therapeutic potential of cannabinoids in MS appears to be comprehensive, and should be given considerable attention.”

The idea of using marijuana to treat MS is not new. This particular study looked at marijuana extracts, but there is also data available on the entire plant’s therapeutic potential for those suffering from MS.

President Obama is hosting a jobs forum at the White House today -- a gathering of business leaders and policy makers who will discuss the creation of new jobs in America. I wish I was there.

If I was in that room, I would stand up, raise my hand, and suggest that we tax and regulate marijuana like alcohol or tobacco. Obama might laugh at me, like he did when we asked him this very question back in March. But I would say it again anyway, because it’s exactly what the president needs to hear. Here is what I would say, if given the opportunity today: 

1. Marijuana is a multibillion dollar a year industry, one that contributes little if anything to the American economy. Why? Because our laws put the industry into the hands of criminals rather than legitimate businesses.

2. The exception to the above is the medical marijuana industry. In the states that have allowed regulated marketplaces, these businesses are booming despite the bad economy. For example, business expos in Michigan are touting the success of medical marijuana growing operations and their potential for creating jobs in the state hit hardest by the recession.

3. Finally, it worked with booze. Just last year, Congress praised the 21^st Amendment for lifting the ban on alcohol sales. A quote from H. CON. RES. 415: “2,500 breweries, distilleries, wineries, and import companies, 2,700 wholesale distributor facilities, over 530,000 retail outlets, and numerous agricultural, packaging, and transportation businesses support the employment of millions of Americans.”

The potential for job creation and economic growth in legal marijuana sales is massive. With a simple policy change we could create a new industry, rivaling the size of Philip Morris or MillerCoors domestically, but with a product that’s safer in every measurable way.

The jobs, the money, and the markets are already in place. Without marijuana prohibition, we could take a multibillion-dollar drain on the economy and turn it into a multibillion-dollar profit.

The Journal of Neuroscience just published a new study that is particularly interesting in light of recent reports that marijuana may effectively substitute for abuse of more dangerous drugs.

In the new study, rats were taught to self-administer heroin and conditioned to associate that behavior with a light that flashed on above the lever that dispensed the heroin. At various stages in the procedure, some of the rats were treated with cannabidiol (CBD), a cannabinoid that doesn’t make you high, but which has a number of really interesting properties.

CBD didn’t have any effect when given to the rats who were actively dosing themselves with heroin, but it had a marked effect on rats who had been abstinent from heroin for two weeks. These rats-in-recovery were again shown the cue light, and those who hadn’t been given CBD immediately resumed pushing the heroin lever, seeking a dose of the drug. But in the CBD rats, this heroin-seeking behavior was markedly reduced – and the effect continued for a full two weeks after the last CBD treatment.

The researchers conclude, “CBD may be a potential treatment for heroin craving and relapse.” It might also imply that high-CBD strains of marijuana could be preferable for those who are trying to stay off of other drugs.

Ah, but how do you know if the marijuana you’re buying is high in CBD (which is probably not the case most of the time)? Well, if it were a legal, regulated product, marijuana could be labeled for cannabinoid content – just like that bottle of wine now tells you, “alcohol 13.8%” or whatever. What a concept.

This holiday season, Facebook users can help MPP and other groups earn money with just the click of a button.

The Chase Community Giving Challenge allows users to help decide which organizations receive $5 million from Chase.

The first round of voting ends Dec. 11, and the top 100 charities at that point will each receive $25,000. (Winners will be announced Dec. 15.) In January, another round of voting starts for one $1 million prize and five $100,000 prizes.

Right now MPP has close to 1,000 votes, but needs more to have a chance at winning. If you support MPP, and have a Facebook account, please vote for MPP here. 

Yesterday, via Twitter, both Adrianne Curry @adriannecurry and Slightly Stoopid @SlightlyStoopid asked their followers to vote for us. Each user gets up to 20 votes, so you can also help support our allies, such as Students for Sensible Drug Policy, or any other organization of your choice.

A new study published in Harm Reduction Journal by researchers at the University of California, Berkley, suggests that marijuana is a safe and effective substitute for alcohol and prescription drugs.

In the study, 40 percent of marijuana users said they have used marijuana to control their alcohol addictions, 66 percent said they used marijuana instead of prescription drugs, and 26 percent said marijuana helped them stay off other illegal drugs.

According to lead researcher Amanda Reiman:

“Substituting cannabis for alcohol has been described as a radical alcohol treatment protocol. This approach could be used to address heavy alcohol use […] People might substitute cannabis, a potentially safer drug than alcohol with less negative side-effects, if it were socially acceptable and available.”

To read the full report here you must subscribe to Complementary Health Practice Review Online.

Yesterday, Israel’s Ministry of Health was ordered to finalize within four months a detailed bill that would regulate the production and marketing of medical marijuana in that country.

Additional measures recommended by a government health committee included making sure that medical marijuana remains affordable for patients and implementing safeguards to prevent the drug from reaching illegal users and merchants.

Once again, Israel’s government has shown a desire to promote the wellbeing of patients who can benefit from medical marijuana—something our federal government continues to avoid.

My  recent post about medical marijuana and  young patients got picked up by the folks over at OpposingViews.com. And that prompted writer Katherine Ellison, whose New York Times story I'd taken issue with to post the following response:

a couple corrections for you

Hi, Bruce --

For the record, my byline is Katherine, not Kathy. And I guess I can understand your frustration at not having a story that reflects your advocate's view of marijuana as a safe , cure-all drug, appropriate for all ages. However, I stand by my reporting, which I think was a responsible effort to bring awareness to an increasing problem of irresponsible doctors given way too much leeway with an untested drug on adolescents.

- kathyellison November 25, 2009 10:28AM

Oh dear. I generally don't like to get into fights with reporters, but I'm grateful that Opposing Views allowed me to post the following response:

First, Katherine, I apologize for using your name as you signed it on your emails to me rather than as published in your byline. Nevertheless, I find it frustrating that you appear to be deliberately misinterpreting both what I've written here and what I said on the phone during our lengthy conversation.

You know full well that I don't consider marijuana a cure-all and that I do not expect you to endorse my opinions in print. I do expect you, in reporting a scientific issue, to actually address the relevant science in a way that will enlighten readers.

Your story failed to explain meaningful scientific evidence provided to you by both me and Paul Armentano suggesting a positive effect of marijuana on ADHD as well as the biochemical basis for such an effect being plausible. You included a scientifically nonsensical quote from Stephen Hinshaw calling marijuana for ADHD "one of the worst ideas of all time" because marijuana disrupts attention and memory in normal people. But we know that the brains of ADHD patients don't work like those of normal people -- which is why stimulants like Ritalin have a calming effect, the exact opposite of their effect on most of us. Did you even bother to ask Hinshaw this obvious followup question?

You also included a cavalier quote from Edward M. Hallowell claiming that marijuana use "can lead to a syndrome in which all the person wants to do all day is get stoned, and they do nothing else" -- without bothering to note that this so-called "amotivational syndrome" has been debunked again and again. One example that I sent you, and which you apparently ignored, was the 1999 Institute of Medicine report commissioned by the White House, which states on pages 107-108, "When heavy marijuana use accompanies these symptoms, the drug is often cited as the cause, but no convincing data demonstrate a causal relationship between marijuana smoking and these behavioral characteristics." Many other expert reviews have come to the same conclusion.

I am not asking you to agree with me or to tout marijuana as a cure-all, which it manifestly is not. As a longtime health journalist myself, all I am asking is for you to do your homework as a reporter.

While many American authorities continue to drag their feet on medical marijuana issues, one of our closest overseas allies is taking another step to help patients for whom marijuana is a safe and reliable treatment.

Sheba Medical Center in Tel Hashomer recently became the first hospital in Israel to administer medical marijuana to qualified patients. After a successful pilot program, the new hospital policy allows medical marijuana patients to use their medication either in smoking rooms or in private rooms with an open window. To further accommodate these patients’ needs, the Israeli Association for the Advancement of Medical Cannabis is now raising money to purchase vaporizers—five of which are already in use at the hospital.

This is just the latest example of Israel and other countries outpacing the United States when it comes to providing seriously ill patients with safe and reliable access to medical marijuana.

Lately there has been a small burst of media fascination with what by most accounts is a rare occurrence: Use of medical marijuana recommended by a physician by patients under 18. Any psychoactive drug, including marijuana, should be used with caution in children, but there is no reason that these infrequent cases should be shocking. Indeed, they should be taken as signposts on the road to urgently-needed research.

Sad as it is to contemplate, kids do get deadly illnesses like cancer and AIDS. Medical marijuana dispensary operator Charles Lynch faced an enhanced federal prison sentence for providing medical marijuana to 17-year-old cancer patient Owen Beck, who survived his cancer partly thanks to Lynch’s help, and who attempted to testify on Lynch’s behalf but was barred from doing so. And millions of young people with attention deficit hyperactivity disorder (ADHD) have been prescribed stimulants like Ritalin and Adderall, whose side effects can include psychotic symptoms and interference with growth, not to mention sudden death when used by patients with some preexisting heart conditions.

Unfortunately, a story in Sunday’s New York Times looking at marijuana as a treatment for young people with ADHD managed to avoid shedding much light on the issue. Instead, the focus seemed to be on sensational quotes ("worst idea ever," "safer than aspirin") rather than a serious look at the science.

Writer Kathy Ellison did briefly reference a study in the journal Schizophrenia Research, but without properly explaining it. Of the 25 young people with ADHD in this study, the marijuana users scored healthier than non-users on nearly every measure of mental functioning, including specific measures of hyperactivity and disorganization. This was particularly striking because in the same study a separate group of individuals at genetic risk for schizophrenia were made worse by marijuana. The published study includes a discussion of the biochemical mechanisms by which marijuana might help ADHD. This is consistent with published case reports that have found a beneficial of THC on ADHD.

Meanwhile, ABC’s “Good Morning America” did a more respectful job in reporting on the mom of an autistic child who says that a small amount of marijuana, administered under a doctor’s care, has literally saved her child’s life. Others have told similar stories.

We don’t know nearly enough yet to state definitively that marijuana is helpful for youthful ADHD and autism. But we do know enough to say that proper research is urgently needed, and that this is a serious enough issue that the media need to treat it seriously.